Selank

Protocol examples

Protocol logic check

Independent evidence

Regulatory status: unapproved or compounded peptide with FDA safety risk flag

Storage

No approved-label storage guidance was identified for this entry. Use conservative sterile handling and see the general storage guidance in the FAQ.

Contraindications & cautions

Evidence varies by item. Some points come from labels, published literature, or regulatory context; others are mechanism-based cautions from the source dataset. Use the sources below to verify details.

• Known hypersensitivity to Selank, tuftsin-derived peptides, or formulation excipients.
• Concurrent use with opioid analgesics: Selank increases endogenous enkephalin tone via enkephalinase inhibition; in subjects already on opioid agonists, the additive mu/delta opioid receptor activity theoretically potentiates opioid effects and may complicate analgesic dosing.
• Concurrent use with benzodiazepines or barbiturates: while Selank does not act on GABA-A receptors, overlapping CNS depressant effects in highly anxiolytic-saturated subjects may produce excessive sedation; use with caution.
• Active severe depressive episode with psychomotor retardation: while Selank has mood-stabilizing properties, its primary anxiolytic action without stimulant properties could theoretically deepen motivational suppression in severely retarded depression; monitor carefully.
• Pregnancy: no clinical safety data.
• Breastfeeding: no safety data.
• Pediatric use: not established.
• Narcolepsy or hypersomnia: Selank's enkephalin-potentiating activity could worsen daytime sleepiness in subjects with pre-existing hypersomnia disorders.

Possible side effects

Evidence varies by item. Some points come from labels, published literature, or regulatory context; others are mechanism-based cautions from the source dataset. Use the sources below to verify details.

• Mild fatigue and sedation at high doses: the most commonly reported adverse effect; dose-dependent; occurs primarily at doses above 500mcg; characterized by a calm, slightly sleepy state that is usually welcome in evening use but problematic for daytime productivity at excessive doses.
• Mild dizziness: uncommon; related to the brief cardiovascular effects of enkephalin potentiation.
• Mild headache: uncommon; transient; reported in a small subset of users in the initial days of a cycle.
• Reduced motivation in some subjects: enkephalin potentiation produces profound emotional calm that, in a minority of subjects, blunts goal-directed drive and ambition; resolve with dose reduction.
• Emotional blunting at high doses: excessive enkephalin tone can produce emotional flatness; this is the upper-dose limit signal that warrants dose reduction.
• Nasal irritation with intranasal formulations: mild; not applicable to subcutaneous administration.
• No withdrawal syndrome: Selank has no physical dependence liability; cessation does not produce rebound anxiety, insomnia, or other withdrawal phenomena that characterize benzodiazepine discontinuation.
• No cognitive impairment: unlike benzodiazepines, Selank does not impair memory formation, reaction time, or processing speed at anxiolytic doses; the opposite is typically observed.
• No respiratory depression: GABA-independent mechanism means Selank carries no overdose risk from respiratory suppression.

Compatibility

The relationships below come from the source site's internal engine and were not verified independently. Treat them as a starting point for a conversation with a clinician. They carry no safety guarantee.

Reported synergistic:

Reported contraindicated combinations:

None listed.

Sources

• https://the source dataset.com/peptide-codex.php
• https://www.fda.gov/drugs/guidance-compliance-regulatory-information/human-drug-compounding
• https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks?pg=3
• PubMed search: Selank